Cancer RemissionPREVACNCT06215365
Study of Health-risk Behaviours (Tobacco, Alcohol or Drug Consumption ; Nutrition ; Sedentary Lifestyle ; Sexual Practices) Among Cancer Survivors
A study testing Adult cancer survivors who have completed their heavy treatments in people with Cancer Remission, run by Hospices Civils de Lyon at 1 site in France.
Trial summary
Cancer is now becoming a chronic condition though it was, until a short time ago, a fatal illness. Thus, according to the French national cancer institute, nearly 4 million French people have been diagnosed with cancer in their lifetime. Read more about this study
- Who is it for?
- Ages 74 to 100 years
- Conditions the study is for
- Cancer Remission
- What is being tested?
- Adult cancer survivors who have completed their heavy treatments
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 46 participants
- Where
- 1 siteFrance
- Study dates
- 12 Feb 2024to 7 May 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 74 to 100 years
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Cancer survivor
- Up to 74 years old
- Less than a year from the end of their heavy treatments
- Participating in JUMP post-cancer day.
Who cannot join
- Patients with cognitive disorders that limit their ability to understand and complete the questionnaire.
- Patients who do not speak, read and write French.
Trial locations and contacts
1 site in 1 country.
About this study
- Cancer is now becoming a chronic condition though it was, until a short time ago, a fatal illness. Thus, according to the French national cancer institute, nearly 4 million French people have been diagnosed with cancer in their lifetime.
- Screening is used to detect the presence of a pathology at an early, infra-clinical stage, or the presence of a risk factor in people who are supposedly healthy.
- There are three organized screening programs in France (breast cancer, colorectal cancer, cervical cancer), as well as many others recommended by learned societies such as the National Authority for Health . However, they are underused, far from European recommendations and government targets.
- According to DREES (research, studies, evaluation and statistic department), public health and primary prevention interventions could have prevented 143 deaths per 100.000 inhabitants, and healthcare interventions could have spared 59 deaths per 100.000 inhabitants, for a total of 202 avoidable deaths per 100.000 inhabitants in France in 2020.
- As for cancers, French national cancer institute estimates the rate of avoidable cancers in France in 2023 at 40%. Breast cancer, for example, is the most common cancer that can be associated with alcohol consumption and estimations suggest that nearly 20.000 breast cancers could be prevented each year (a third of new cancer cases in 2018).
- In France, prevention accounts for 5.5% of healthcare expenses in 2021, with 46% for individual primary prevention, 41% for individual secondary prevention and 12% for collective prevention and prevention programs. These healthcare expenses must be set against the social cost of each risk factor, to see how important they are.
- Relative burden of cancer and noncancer mortality among long-term survivors of breast, prostate, and colorectal cancer in the US has been demonstrated. It shows that "patients with low oncologic risk at the time of diagnosis had at least 3-fold higher risk of noncancer death compared with death from the index cancer".
- In France, medical desertification is a reality. Now, according to the VICAN-5 study, nearly a third of cancer patients are not followed up by general practitioners. Though primary prevention is one of GP's prerogatives and a governmental priority.
- There is a high interest in screening and preventive action to limit the risk of other avoidable pathologies, whether cancerous or not.
The research hypothesis is that a customized screening will enable the implementation of comprehensive preventive action to limit the onset of avoidable diseases (second cancer or other pathology) for cancer survivors.
- Conditions
- Cancer Remission
- Being tested
- Adult cancer survivors who have completed their heavy treatments
- Keywords
- Health-risk behaviours, post-cancer, prevention, screening, vaccination
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Adult cancer survivors who have completed their heavy treatmentsBehavioural
The study will be presented to the patient who can refuse to participate. The digital version of the questionnaire will be handed out, if the patient does not object after a period of thinking, when he or she comes to the day hospital for his or her JUMP Day. The study will therefore take place at a single point in time, and no pre-inclusion or follow-up visits are planned as part of this protocol.
Completing the questionnaire takes about 15 to 20 minutes. All questions are designed to meet the stated objectives. No personally identifiable data is collected.
| Study group | Role | What they receive |
|---|---|---|
| Adult cancer survivors (until 74 years old) who have completed their heavy treatments | Experimental | Adult cancer survivors (until 74 years old) who have completed their heavy treatments (chemotherapy, radio-chemotherapy, …) and that are taking part in the "JUMP post-cancer day" which is a multidisciplinary evaluation carried out at the end of treatments.
They must not have cognitive disorders that limit their ability to understand and complete the questionnaire. Also, they have to speak, read and write French language.
The study will be presented to the patient who can refuse to participate. The digital version of the questionnaire will be handed out, if the patient does not object after a period of thinking, when he or she comes to the day hospital for his or her JUMP Day. The study will therefore take place at a single point in time, and no pre-inclusion or follow-up visits are planned as part of this protocol.
Completing the questionnaire takes about 15 to 20 minutes. All questions are designed to meet the stated objectives. No personally identifiable data is collected. Receives: Behavioral: Adult cancer survivors who have completed their heavy treatments |
What is being measured
The primary outcome is the main question the study is designed to answer.
The percentage of people in the studied population with at least one modifiable health risk behavior among cancer survivors.
Modifiable health risk behaviors are: tobacco, alcohol or drug consumption ; nutrition ; sedentary lifestyle ; sexual practices.
Measured: through study completion, an average of 2 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jan 2024
- Study start12 Feb 2024
- Primary completion7 May 2024
- Study completion7 May 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Cancer RemissionStudies of the same condition, open and under way.
- More trials run by Hospices Civils de LyonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 46 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hospices Civils de Lyon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06215365
- Sponsor's protocol ID
- 69HCL23_1306
- Acronym
- PREVAC
- Status last verified
- Nov 2025
- First submitted
- 27 Dec 2023
- Last updated
- 21 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
STOLTZ Justine. Mise en place d'une intervention d'évaluation des comportements à risques et de dépistage dans l'après-cancer (CO5). Congrès PARKOURS onco-hémato 2025, Auditorium Pasteur, jeudi 30 janvier 2025, 17:45-18:00 (Lyon).
Study at a glance
From the registry record, last updated by the sponsor on 21 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of Health-risk Behaviours (Tobacco, Alcohol or Drug Consumption ; Nutrition ; Sedentary Lifestyle ; Sexual Practices) Among Cancer Survivors
- ClinicalTrials.gov ID
- NCT06215365
- Acronym / sponsor ID
- PREVAC / 69HCL23_1306
- Conditions
- Cancer Remission
- Keywords
- Health-risk behaviours, post-cancer, prevention, screening, vaccination
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 46 participants (actual)
- Lead sponsor
- Hospices Civils de LyonUniversity, hospital or other
- Study start
- 12 Feb 2024 (actual)
- Primary completion
- 7 May 2024 (actual)
- Study completion
- 7 May 2024 (actual)
- First posted
- 22 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- Cancer is now becoming a chronic condition though it was, until a short time ago, a fatal illness. Thus, according to the French national cancer institute, nearly 4 million French people have been diagnosed with cancer in their lifetime.
- Screening is used to detect the presence of a pathology at an early, infra-clinical stage, or the presence of a risk factor in people who are supposedly healthy.
- There are three organized screening programs in France (breast cancer, colorectal cancer, cervical cancer), as well as many others recommended by learned societies such as the National Authority for Health . However, they are underused, far from European recommendations and government targets.
- According to DREES (research, studies, evaluation and statistic department), public health and primary prevention interventions could have prevented 143 deaths per 100.000 inhabitants, and healthcare interventions could have spared 59 deaths per 100.000 inhabitants, for a total of 202 avoidable deaths per 100.000 inhabitants in France in 2020.
- As for cancers, French national cancer institute estimates the rate of avoidable cancers in France in 2023 at 40%. Breast cancer, for example, is the most common cancer that can be associated with alcohol consumption and estimations suggest that nearly 20.000 breast cancers could be prevented each year (a third of new cancer cases in 2018).
- In France, prevention accounts for 5.5% of healthcare expenses in 2021, with 46% for individual primary prevention, 41% for individual secondary prevention and 12% for collective prevention and prevention programs. These healthcare expenses must be set against the social cost of each risk factor, to see how important they are.
- Relative burden of cancer and noncancer mortality among long-term survivors of breast, prostate, and colorectal cancer in the US has been demonstrated. It shows that "patients with low oncologic risk at the time of diagnosis had at least 3-fold higher risk of noncancer death compared with death from the index cancer".
- In France, medical desertification is a reality. Now, according to the VICAN-5 study, nearly a third of cancer patients are not followed up by general practitioners. Though primary prevention is one of GP's prerogatives and a governmental priority.
- There is a high interest in screening and preventive action to limit the risk of other avoidable pathologies, whether cancerous or not.
The research hypothesis is that a customized screening will enable the implementation of comprehensive preventive action to limit the onset of avoidable diseases (second cancer or other pathology) for cancer survivors.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Adult cancer survivors (until 74 years old) who have completed their heavy treatments | Experimental | Behavioral: Adult cancer survivors who have completed their heavy treatmentsAdult cancer survivors (until 74 years old) who have completed their heavy treatments (chemotherapy, radio-chemotherapy, …) and that are taking part in the "JUMP post-cancer day" which is a multidisciplinary evaluation carried out at the end of treatments. They must not have cognitive disorders that limit their ability to understand and complete the questionnaire. Also, they have to speak, read and write French language. The study will be presented to the patient who can refuse to participate. The digital version of the questionnaire will be handed out, if the patient does not object after a period of thinking, when he or she comes to the day hospital for his or her JUMP Day. The study will therefore take place at a single point in time, and no pre-inclusion or follow-up visits are planned as part of this protocol. Completing the questionnaire takes about 15 to 20 minutes. All questions are designed to meet the stated objectives. No personally identifiable data is collected. |
Who may qualify
- Ages
- 74 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (4 listed)
- Cancer survivor
- Up to 74 years old
- Less than a year from the end of their heavy treatments
- Participating in JUMP post-cancer day.
Key exclusion criteria (2 listed)
- Patients with cognitive disorders that limit their ability to understand and complete the questionnaire.
- Patients who do not speak, read and write French.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Adult cancer survivors who have completed their heavy treatmentsThe study will be presented to the patient who can refuse to participate. The digital version of the questionnaire will be handed out, if the patient does not object after a period of thinking, when he or she comes to the day hospital for his or her JUMP Day. The study will therefore take place at a single point in time, and no pre-inclusion or follow-up visits are planned as part of this protocol. Completing the questionnaire takes about 15 to 20 minutes. All questions are designed to meet the stated objectives. No personally identifiable data is collected. | Behavioural | Adult cancer survivors (until 74 years old) who have completed their heavy treatments |
Primary outcome
The percentage of people in the studied population with at least one modifiable health risk behavior among cancer survivors.
Time frame: through study completion, an average of 2 months
Modifiable health risk behaviors are: tobacco, alcohol or drug consumption ; nutrition ; sedentary lifestyle ; sexual practices.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Nov 2025.
- Results publicationSTOLTZ Justine. Mise en place d'une intervention d'évaluation des comportements à risques et de dépistage dans l'après-cancer (CO5). Congrès PARKOURS onco-hémato 2025, Auditorium Pasteur, jeudi 30 janvier 2025, 17:45-18:00 (Lyon).
- Individual participant dataSharing planned: No
Related trials for Cancer Remission
RecruitingPhase 1
Vididencel in CML-CP Patients With MRD
CML (Chronic Myelogenous Leukemia)
Active, not recruitingPhase 2
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Not yet recruitingPhase 2
Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and Lymphoma
Acute Lymphoblastic Leukemia in Remission, Hodgkin Lymphoma in Remission
Recruiting
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
B-All, Acute Lymphoblastic Leukemia
RecruitingPhase 3
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
Asthma Control
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Adult cancer survivors who have completed their heavy treatments in people with Cancer Remission, run by Hospices Civils de Lyon at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The percentage of people in the studied population with at least one modifiable health risk behavior among cancer survivors. (time frame: through study completion, an average of 2 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06215365, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2025.